Portico Next Generation Approval Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Portico™ NG (Navitor) Valve and FlexNav™ Delivery System: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Study summary
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.
Eligibility
Primary outcome measure(s)
- Primary Safety Endpoint is All-cause Mortality — at 30 days
All-cause mortality is defined as the total number of deaths in each cohort at 30 days. - Primary Effectiveness Endpoint is Moderate or Greater Paravalvular Leak — at 30 days
Number of participants with moderate or greater paravalvular leak at 30 days.
Trial sites (28)
| Facility | City | Region | Status |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | |
| Los Robles Regional Medical Center | Thousand Oaks | California | |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | |
| Advocate Christ Medical Center | Oak Lawn | Illinois | |
| Ascension St. Vincent | Indianapolis | Indiana | |
| Ascension Via Christi Hospitals Wichita | Wichita | Kansas | |
| Sparrow Clinical Research Institute | Lansing | Michigan | |
| Minneapolis Heart Institute Foundation | Minneapolis | Minnesota | |
| Morristown Medical Center | Morristown | New Jersey | |
| Albany Medical Center | Albany | New York | |
| Columbia Univ. Medical Center/NewYork-Presbyterian Hospital | New York | New York | |
| Montefiore Medical Center - Moses Campus | New York | New York | |
| Mission Hospital | Asheville | North Carolina | |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | |
| Providence St. Vincent Medical Center | Portland | Oregon | |
| UPMC | Pittsburgh | Pennsylvania | |
| Baptist Memorial Hospital | Memphis | Tennessee | |
| Houston Methodist | Houston | Texas | |
| Baylor Scott & White - The Heart Hospital Plano | Plano | Texas | |
| Intermountain St. George Regional Hospital | St. George | Utah | |
| Sentara Norfolk General Hospital | Norfolk | Virginia | |
| St. Andrew's Hospital | Adelaide | South Australia | |
| The Alfred Hospital | Melbourne | Victoria | |
| Fiona Stanley Hospital | Murdoch | Western Australia | |
| Rigshospitalet | Copenhagen | Denmark | |
| Policlinico San Donato | San Donato Milanese | Lombard | |
| Royal Victoria Hospital | Belfast | Northern Ireland | |
| Morriston Hospital - ABM University Health Board | Morriston | SWANSEA |
More Abbott Medical Devices trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04011722 on ClinicalTrials.gov ↗ ← All trials in the USA